Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

August 31, 2008

Conditions
Bipolar Disorder
Interventions
DRUG

L-Thyroxine

L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg

DRUG

Placebo

Trial Locations (5)

Unknown

University of California in Los Angeles, Los Angeles

Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, Berlin

Department of Psychiatry, LWL University Hospital, Ruhr University Bochum, Bochum, Germany, Bochum

Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, Dresden

Department of Psychiatry and Psychotherapy, University of Göttingen, Germany, Göttingen

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Charite University, Berlin, Germany

OTHER

NCT01528839 - Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression | Biotech Hunter | Biotech Hunter